Determination of radioactivity in infant, juvenile and adult rat brains after injection of anti-influenza drug [11C]oseltamivir using PET and autoradiography

Neuroscience Letters

Volumn 495, Issue 3, 2011, Pages 187-191

  Hatori, Akiko ^a   Yui, Joji ^a   Yanamoto, Kazuhiko ^a   Yamasaki, Tomoteru ^a   Kawamura, Kazunori ^a   Takei, Makoto ^a,b   Arai, Takuya ^a   Fukumura, Toshimitsu ^a   Zhang, Ming Rong ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b Department of Engineering and Environment   (Japan)

Author keywords

11C oseltamivir; Anti influenza drug; Autoradiography; PET; Tamiflu

Indexed keywords

CARBON 11; CYCLOSPORIN A; OSELTAMIVIR; RADIOLIGAND;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN; CEREBELLUM; CONTROLLED STUDY; INFANT; JUVENILE; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RAT;

AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; ANTIVIRAL AGENTS; AREA UNDER CURVE; AUTORADIOGRAPHY; BRAIN; BRAIN MAPPING; CARBON ISOTOPES; MALE; OSELTAMIVIR; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 79955629287     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.03.055     Document Type: Article

References (25)

1. Abdel-Rahman S.M., Newland J.G., Kearns G.L. Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant. Paediatr. Drugs 2011, 13:19-31.
2. Arai T., Konno F., Ogawa M., Zhang M.-R., Suzuki K. The first synthesis of [11C]oseltamivir: a tool for elucidating the relationship between Tamiflu and its adverse effects on the central nervous system. J. Labelled Compd. Radiopharm. 2009, 52:350-354.
3. Cornford E.M., Cornford M.E. Nutrient transport and the blood-brain barrier in developing animals. Fed. Proc. 1986, 45:2065-2072.
4. De Clercq E., Neyts J. Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention. Trends Pharmacol. Sci. 2007, 28:280-285.
5. Dobbing J., Sands J. Quantitative growth and development of human brain. Arch. Dis. Child. 1973, 48:757-767.
6. Duvernoy H.M., Risold P.Y. The circumventricular organs: an atlas of comparative anatomy and vascularization. Brain Res. Rev. 2007, 56:119-147.
7. Hama R. Oseltamivir's adverse reactions: fifty sudden deaths may be related to central suppression. BMJ 2007, 335:59.
8. Hatori A., Arai T., Yanamoto K., Yamasaki T., Kawamura K., Yui J., Konno F., Nakao R., Suzuki K., Zhang M.-R. Biodistribution and metabolism of the anti-influenza drug [11C]oseltamivir and its active metabolite [11C]Ro 64-0802 in mice. Nucl. Med. Biol. 2009, 36:47-55.
9. He G., Massarella J., Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 1999, 37:471-484.
10. Izumi Y., Tokuda K., O'dell K.A., Zorumski C.F., Narahashi T. Neuroexcitatory actions of Tamiflu and its carboxylate metabolite. Neurosci. Lett. 2007, 426:54-58.
11. Johanson C.E. Permeability and vascularity of the developing brain: cerebellum vs cerebral cortex. Brain Res. 1980, 190:3-16.
12. Matsuoka Y., Okazaki M., Kitamura Y., Taniguchi T. Developmental expression of P-glycoprotein (multidrug resistance gene product) in the rat brain. J. Neurobiol. 1999, 39:383-392.
13. Morimoto K., Nakakariya M., Shirasaka Y., Kakinuma C., Fujita T., Tamai I., Ogihara T. Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein. Drug Metab. Dispos. 2008, 36:6-9.
14. Ogihara T., Kano T., Wagatsuma T., Wada S., Yabuuchi H., Enomoto S., Morimoto K., Shirasaka Y., Kobayashi S., Tamai I. Oseltamivir (Tamiflu) is a substrate of peptide transporter 1. Drug Metab. Dispos. 2009, 37:1676-1681.
15. Okamoto S., Kamiya I., Kishida K., Shimakawa T., Fukui T., Morimoro T. Experience with oseltamivir for infants younger than 1 year old in Japan. Pediatr. Infect. Dis. J. 2005, 24:575-576.
16. Ono H., Nagano Y., Matsunami N., Sugiyama S., Yamamoto S., Tanabe M. Oseltamivir, an anti-influenza virus drug, produces hypothermia in mice: comparison among oseltamivir, zanamivir and diclofenac. Biol. Pharm. Bull. 2008, 31:638-642.
17. Ose A., Kusuhara H., Yamatsugu K., Kanai M., Shibasaki M., Fujita T., Yamamoto A., Sugiyama Y. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Drug Metab. Dispos. 2008, 36:427-434.
18. Rapoport S.I., Ohno K., Fredericks W.R., Pettigrew K.D. Regional cerebrovascular permeability to [14C]sucrose after osmotic opening of the blood-brain barrier. Brain Res. 1978, 150:653-657.
19. Saunders N.R. Ontogeny of the blood-brain barrier. Exp. Eye Res. 1977, (Suppl.):523-550.
20. Saunders N.R., Knott G.W., Dziegielewska K.M. Barriers in the immature brain. Cell. Mol. Neurobiol. 2000, 20:29-40.
21. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A., van der Valk M.A., Robanus-Maandag E.C., te Riele H.P., Berns A.J.M., Borst P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increase sensitivity to drugs. Cell 1994, 77:491-502.
22. Smith J.R. Oseltamivir in human avian influenza infection. J. Antimicrob. Chemother. 2010, 65(Suppl. 2):ii25-ii33.
23. Usami A., Sasaki T., Satoh N., Akiba T., Yokoshima S., Fukuyama T., Yamatsugu K., Kanai M., Shibasaki M., Matsuki N., Ikegaya Y. Oseltamivir enhances hippocampal network synchronization. J. Pharmacol. Sci. 2008, 106:659-662.
24. Wutzler P., Vogel G. Neuraminidase inhibitors in the treatment of influenza A and B-overview and case reports. Infection 2000, 28:261-266.
25. Yoshino T., Nishijima K., Shioda K., Yui K., Kato S. Oseltamivir (Tamiflu) increases dopamine levels in the rat medial prefrontal cortex. Neurosci. Lett. 2008, 438:67-69.